As shown in Figures 5A–C, HERA-CD27L treatment produced dose-dependent tumor-growth inhibition (TGI) compared to the control group, including 48% TGI at 10 mg/kg b.w. HERA-CD27L (p < 0.05). The gene discussed is ERAL1; the disease is neoplasm.